Table 2 Interference of maternally derived antibodies (MDA) with vaccine efficacy in terms of serological and production parameters
Pathogen | Vaccination age (in weeks) | Interference on antibody seroconversion (assay used)a | Interference on production parameters (parameters evaluated)b | References |
|---|---|---|---|---|
SIV | 3 | Yes (HI assay) | NE | [23] |
Different age groups | Yes (HI assay) | NE | [67] | |
16 | Yes (HI assay, ELISA) | NE | [68] | |
PRRSV | 3 | Yes (ELISA, VNT) | NE | [71] |
3 & 4 | Yes (ELISA) | NE | [82] | |
PCV-2 | 4 | Yes (ELISA) | No (ADWG) | [96] |
3 | NE | No (ADWG) | [93] | |
3 | Yes (IPMA, VNT) | NE | [17] | |
3 | Yes (ELISA) | NE | [95] | |
3 | Yes (IPMA) | NE | [97] | |
4 | Yes (IPMA) | No (ADWG) | [98] | |
Different age groups | Yes (ELISA) | Yes (ADWG) | [99] | |
4 | Yes (ELISA) | NE | [60] | |
3 | Yes (ELISA) | Only when S/P values at vaccination are extremelly high (ADWG) | [21] | |
2 | NE | No (ADWG, mortality) | [100] | |
M. hyopneumoniae | 1 & 4 | Yes (ELISA) | No (ADWG, mortality) | [115] |
2 | Yes (ELISA) | NE | [112] | |
1 & 4 | Yes (NC) | NE | [114] | |
1 | No (ELISA) | NE | [109] | |
1 | No (ELISA) | NE | [111] | |
1 | Yes (ELISA) | NE | [116] | |
1 | Yes (ELISA) | NE | [113] | |
A. pleuropneumoniae | 6 | Yes (ELISA) | NE | [128] |
6 | Yes (ELISA) | NE | [123] |